Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.
Adenocarcinoma
Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.
Adenocarcinoma
Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin.
Adenocarcinoma
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Adenocarcinoma
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
Adenocarcinoma
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy.
Adenocarcinoma
Histone Methyltransferases Useful in Gastric Cancer Research.
Adenocarcinoma
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.
Adenocarcinoma
Robust expression of EZH2 in endocervical neoplastic lesions.
Adenocarcinoma
SETDB1 in cancer: overexpression and its therapeutic implications.
Adenocarcinoma
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Adenocarcinoma of Lung
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Adenocarcinoma of Lung
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Adenocarcinoma of Lung
Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Adenocarcinoma of Lung
Hypoxic tumor-derived exosomal circular RNA SETDB1 promotes invasive growth and EMT via the miR-7/Sp1 axis in lung adenocarcinoma.
Adenocarcinoma of Lung
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Adenoma
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Adenoma
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
Alzheimer Disease
Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease.
Alzheimer Disease
Two conserved epigenetic regulators prevent healthy ageing.
Anhedonia
Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B.
Anus, Imperforate
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Arthritis, Rheumatoid
Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis.
Asthma
An efficient hybrid feature selection method to identify potential biomarkers in common chronic lung inflammatory diseases.
Asthma
An epigenetic silencing pathway controlling T helper 2 cell lineage commitment.
Astrocytoma
Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1.
Atherosclerosis
Histone Methyltransferase Enhancer of Zeste Homolog 2-Mediated ABCA1 Promoter DNA Methylation Contributes to the Progression of Atherosclerosis.
Atherosclerosis
Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.
Autoimmune Diseases
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Avian Leukosis
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
Bacterial Infections
Signatures of selection reveal candidate genes involved in economic traits and cold acclimation in five Swedish cattle breeds.
Biliary Tract Neoplasms
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Blast Crisis
Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia.
Blister
The CURLY LEAF interacting protein BLISTER controls expression of polycomb-group target genes and cellular differentiation of Arabidopsis thaliana.
Bone Marrow Failure Disorders
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
Bone Marrow Failure Disorders
PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation.
Brain Injuries
Post-Treatment Sevoflurane Protects Against Hypoxic-Ischemic Brain Injury in Neonatal Rats by Downregulating Histone Methyltransferase G9a and Upregulating Nuclear Factor Erythroid 2-Related Factor 2 (NRF2).
Brain Ischemia
Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia.
Brain Neoplasms
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Brain Neoplasms
HP1? is highly expressed in glioma cells and facilitates cell proliferation and survival.
Brain Neoplasms
[Epigenetic analyses of brain tumor stem cells]
Breast Neoplasms
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Breast Neoplasms
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Breast Neoplasms
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
Breast Neoplasms
DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor.
Breast Neoplasms
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
Breast Neoplasms
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.
Breast Neoplasms
Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.
Breast Neoplasms
EHMT2 is a metastasis regulator in breast cancer.
Breast Neoplasms
EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Breast Neoplasms
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
Breast Neoplasms
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.
Breast Neoplasms
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Breast Neoplasms
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Breast Neoplasms
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Breast Neoplasms
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Breast Neoplasms
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Breast Neoplasms
Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Breast Neoplasms
Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.
Breast Neoplasms
Impact of histone methyltransferase SUV420H2 in breast cancer.
Breast Neoplasms
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.
Breast Neoplasms
Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.
Breast Neoplasms
Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Breast Neoplasms
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Breast Neoplasms
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.
Breast Neoplasms
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Breast Neoplasms
Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance.
Breast Neoplasms
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Breast Neoplasms
Loss of DNA Methylation and Histone H4 Lysine 20 Trimethylation in Human Breast Cancer Cells is Associated with Aberrant Expression of DNA Methyltransferase 1, Suv4-20h2 Histone Methyltransferase and Methyl-Binding Proteins.
Breast Neoplasms
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Breast Neoplasms
microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8.
Breast Neoplasms
MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Breast Neoplasms
Novel strategies for molecular targeting to cancer.
Breast Neoplasms
PRMT2 and ROR? expression are associated with breast cancer survival outcomes.
Breast Neoplasms
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Breast Neoplasms
Pygo2 associates with MLL2 histone methyltransferase (HMT) and GCN5 histone acetyltransferase (HAT) complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion.
Breast Neoplasms
RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.
Breast Neoplasms
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Breast Neoplasms
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Breast Neoplasms
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
Breast Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Breast Neoplasms
SETDB1 induces epithelial?mesenchymal transition in breast carcinoma by directly binding with Snail promoter.
Breast Neoplasms
SETDB1 regulates SMAD7 expression for breast cancer metastasis.
Breast Neoplasms
Setdb1, a novel interactor of ?Np63, is involved in breast tumorigenesis.
Breast Neoplasms
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Breast Neoplasms
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
Breast Neoplasms
Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
Breast Neoplasms
The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
Breast Neoplasms
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
Breast Neoplasms
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Breast Neoplasms
The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Breast Neoplasms
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Breast Neoplasms
The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
Breast Neoplasms
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Breast Neoplasms
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.
Breast Neoplasms
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis.
Breast Neoplasms
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
Carcinogenesis
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Carcinogenesis
Abnormal overexpression of G9a in melanoma cells promotes cancer progression via upregulation of the Notch1 signaling pathway.
Carcinogenesis
Altered telomere homeostasis and resistance to skin carcinogenesis in Suv39h1 transgenic mice.
Carcinogenesis
Arsenic and benzo[a]pyrene co-exposure acts synergistically in inducing cancer stem cell-like property and tumorigenesis by epigenetically down-regulating SOCS3 expression.
Carcinogenesis
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
Carcinogenesis
c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.
Carcinogenesis
Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Carcinogenesis
Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.
Carcinogenesis
Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
Carcinogenesis
Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Carcinogenesis
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Carcinogenesis
Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.
Carcinogenesis
Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
Carcinogenesis
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Carcinogenesis
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
Carcinogenesis
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Carcinogenesis
Emerging role of SETDB1 as a therapeutic target.
Carcinogenesis
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Carcinogenesis
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
Carcinogenesis
Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis.
Carcinogenesis
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Carcinogenesis
EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro.
Carcinogenesis
Fine-tuning AKT kinase activity through direct lysine methylation.
Carcinogenesis
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
Carcinogenesis
GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.
Carcinogenesis
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Carcinogenesis
Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Carcinogenesis
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Carcinogenesis
Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro.
Carcinogenesis
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
Carcinogenesis
Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Carcinogenesis
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Carcinogenesis
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Carcinogenesis
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Carcinogenesis
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Carcinogenesis
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Carcinogenesis
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.
Carcinogenesis
Increased Expression of EZH2 in Merkel Cell Carcinoma Is Associated with Disease Progression and Poorer Prognosis.
Carcinogenesis
Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
Carcinogenesis
JAK signaling globally counteracts heterochromatic gene silencing.
Carcinogenesis
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Carcinogenesis
Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.
Carcinogenesis
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Carcinogenesis
Monomethyltransferase SET8 facilitates hepatocellular carcinoma growth by enhancing aerobic glycolysis.
Carcinogenesis
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
Carcinogenesis
Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Carcinogenesis
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Carcinogenesis
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
Carcinogenesis
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Carcinogenesis
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Carcinogenesis
Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Carcinogenesis
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Carcinogenesis
Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.
Carcinogenesis
Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects?
Carcinogenesis
SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
Carcinogenesis
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
Carcinogenesis
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Carcinogenesis
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Carcinogenesis
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Carcinogenesis
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
Carcinogenesis
Setdb1, a novel interactor of ?Np63, is involved in breast tumorigenesis.
Carcinogenesis
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Carcinogenesis
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
Carcinogenesis
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Carcinogenesis
Surveillance of Retroelement Expression and Nucleic-Acid Immunity by Histone Methyltransferase SETDB1.
Carcinogenesis
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
Carcinogenesis
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Carcinogenesis
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Carcinogenesis
The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
Carcinogenesis
The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
Carcinogenesis
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.
Carcinogenesis
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Carcinogenesis
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
Carcinogenesis
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Carcinogenesis
The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.
Carcinogenesis
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Carcinogenesis
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Carcinogenesis
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Carcinogenesis
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Carcinogenesis
[Histone methylation and its relationship with cancer].
Carcinoma
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Carcinoma
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Carcinoma
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Carcinoma
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.
Carcinoma
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Carcinoma
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Carcinoma
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Carcinoma
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Carcinoma
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Carcinoma
Enhancer of Zeste Homolog 2 Expression Is Associated With Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma: A Comparative Study and Review of the Literature.
Carcinoma
Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.
Carcinoma
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Carcinoma
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Carcinoma
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Carcinoma
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Carcinoma
Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver.
Carcinoma
Histone methyltransferase SET8 is regulated by miR-192/215 and induces oncogene-induced senescence via p53-dependent DNA damage in human gastric carcinoma cells.
Carcinoma
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Carcinoma
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Carcinoma
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Carcinoma
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Carcinoma
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
Carcinoma
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Carcinoma
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Carcinoma
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Carcinoma
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Carcinoma
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
Carcinoma
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Carcinoma
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
Carcinoma
SETDB1 in cancer: overexpression and its therapeutic implications.
Carcinoma
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Carcinoma
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
Carcinoma
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
Carcinoma
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
Carcinoma
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
Carcinoma
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Carcinoma
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Carcinoma
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Carcinoma
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Carcinoma
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Carcinoma
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Carcinoma
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Carcinoma
[DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells].
Carcinoma, Adenoid Cystic
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Carcinoma, Hepatocellular
A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome.
Carcinoma, Hepatocellular
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Carcinoma, Hepatocellular
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months.
Carcinoma, Hepatocellular
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Carcinoma, Hepatocellular
Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma.
Carcinoma, Hepatocellular
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
Carcinoma, Hepatocellular
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c.
Carcinoma, Hepatocellular
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122.
Carcinoma, Hepatocellular
Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Carcinoma, Hepatocellular
Knockdown of Histone Methyltransferase hSETD1A Inhibits Progression, Migration, and Invasion in Human Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
Carcinoma, Hepatocellular
SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas.
Carcinoma, Hepatocellular
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Carcinoma, Hepatocellular
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Carcinoma, Hepatocellular
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Carcinoma, Hepatocellular
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Carcinoma, Hepatocellular
TERT promoter mutations in primary liver tumors.
Carcinoma, Hepatocellular
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Carcinoma, Hepatocellular
[Effect of Basil Polysaccharide on Histone H3K9me2 Methylation and Expression of G9a and JMJD1A in Hepatoma Cells Under Hypoxic Conditions].
Carcinoma, Merkel Cell
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Carcinoma, Non-Small-Cell Lung
A regulatory circuitry comprising TP53, miR-29 family, and SETDB1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Carcinoma, Non-Small-Cell Lung
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Carcinoma, Non-Small-Cell Lung
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Carcinoma, Non-Small-Cell Lung
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
Carcinoma, Non-Small-Cell Lung
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
Carcinoma, Non-Small-Cell Lung
SETDB1 in cancer: overexpression and its therapeutic implications.
Carcinoma, Non-Small-Cell Lung
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression.
Carcinoma, Renal Cell
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Carcinoma, Renal Cell
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
Carcinoma, Renal Cell
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
Carcinoma, Small Cell
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Carcinoma, Squamous Cell
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Carcinoma, Squamous Cell
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Carcinoma, Squamous Cell
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Carcinoma, Squamous Cell
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver.
Carcinoma, Squamous Cell
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Carcinoma, Squamous Cell
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
Carcinoma, Squamous Cell
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Cardiomegaly
Chromatin modifications remodel cardiac gene expression.
Cardiomegaly
Histone Methyltransferase G9a is Required for Cardiomyocyte Homeostasis and Hypertrophy.
Cardiomegaly
Histone Methyltransferase SET1 Mediates Angiotensin II-Induced Endothelin-1 Transcription and Cardiac Hypertrophy in Mice.
Cardiomegaly
Interplay of chromatin modifications and non-coding RNAs in the heart.
Cardiomegaly
Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy.
Cardiomegaly
Six1 is down-regulated in end-stage human dilated cardiomyopathy independently of Ezh2.
Cardiomyopathies
ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Cardiomyopathies
Correction to: ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Cardiomyopathy, Dilated
H3K9 histone methyltransferase G9a ameliorates dilated cardiomyopathy via the downregulation of cell adhesion molecules.
Cardiomyopathy, Dilated
The Histone Methyltransferase Mixed Lineage Leukemia (MLL) 3 May Play a Potential Role on Clinical Dilated Cardiomyopathy.
Cardiovascular Diseases
EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Carotid Artery Injuries
Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.
Central Nervous System Diseases
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
CHARGE Syndrome
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Cholangiocarcinoma
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Cholangiocarcinoma
EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
Cholangiocarcinoma
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Cholangiocarcinoma
miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
Choline Deficiency
Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain.
Chondrosarcoma
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Classical Swine Fever
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
Cleft Palate
Retinoic acid inhibits histone methyltransferase Whsc1 during palatogenesis.
Cockayne Syndrome
Activation of RNA polymerase I transcription by cockayne syndrome group B protein and histone methyltransferase G9a.
Cockayne Syndrome
Cockayne syndrome group B deficiency reduces H3K9me3 chromatin remodeler SETDB1 and exacerbates cellular aging.
Colitis
Gut stem cell necroptosis by genome instability triggers bowel inflammation.
Colitis
Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation.
Colitis
The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis.
Colonic Neoplasms
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
Colonic Neoplasms
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Colonic Neoplasms
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Colonic Neoplasms
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
Colonic Neoplasms
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Colonic Neoplasms
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
Colonic Neoplasms
Novel strategies for molecular targeting to cancer.
Colonic Neoplasms
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
Colonic Neoplasms
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Colonic Neoplasms
Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma.
Colonic Neoplasms
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
Colorectal Neoplasms
Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer.
Colorectal Neoplasms
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
Colorectal Neoplasms
Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.
Colorectal Neoplasms
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
Colorectal Neoplasms
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene.
Colorectal Neoplasms
G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.
Colorectal Neoplasms
Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer.
Colorectal Neoplasms
Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation through the STAT1-CCND1/CDK6 Axis.
Colorectal Neoplasms
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Colorectal Neoplasms
Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2.
Colorectal Neoplasms
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Colorectal Neoplasms
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Colorectal Neoplasms
Network Inference Analysis Identifies SETDB1 as a Key Regulator for Reverting Colorectal Cancer Cells into Differentiated Normal-Like Cells.
Colorectal Neoplasms
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
Colorectal Neoplasms
NSD1 encoding a histone methyltransferase exhibits frameshift mutations in colorectal cancers.
Colorectal Neoplasms
Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Colorectal Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Colorectal Neoplasms
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
Colorectal Neoplasms
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Colorectal Neoplasms
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
Coronary Disease
Novel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes.
COVID-19
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.
COVID-19
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Crohn Disease
Gut stem cell necroptosis by genome instability triggers bowel inflammation.
Cysts
dSETDB1 and SU(VAR)3-9 sequentially function during germline-stem cell differentiation in Drosophila melanogaster.
Cysts
Histone methyltransferase 1 regulates the encystation process in the parasite Giardia lamblia.
Diabetes Mellitus
Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 1
Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Histone H2AK119 and H2BK120 Monoubiquitination Modulate SET7/9 and SUV39H1 in Type 1 Diabetes Induced Renal Fibrosis.
Diabetes Mellitus, Type 1
Type 1 Diabetes and the HLA Region: Genetic Association Besides Classical HLA Class II Genes.
Diabetes Mellitus, Type 2
Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Diabetes Mellitus, Type 2
The Histone Methyltransferase MLL1 Directs Macrophage-Mediated Inflammation in Wound Healing and Is Altered in a Murine Model of Obesity and Type 2 Diabetes.
Diabetes, Gestational
Gestational Diabetes Mellitus Impairs Fetal Endothelial Cell Functions Through a Mechanism Involving MicroRNA-101 and Histone Methyltransferase Enhancer of Zester Homolog-2.
Diabetic Cardiomyopathies
MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy.
Down Syndrome
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
Down Syndrome
PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation.
Dyskeratosis Congenita
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
Dyskeratosis Congenita
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
Dystonia
Corrigendum: Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Dystonia
Generalized dystonia associated with mutation in the histone methyltransferase gene KMT2B (DYT28) and white matter abnormalities.
Dystonia
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia.
Dystonia
Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype-phenotype correlations of all published cases.
Dystonia
Identification of Novel KMT2B Variants in Chinese Dystonia Patients via Whole-Exome Sequencing.
Dystonia
Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Dystonia
Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.
Dystonia
Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B.
Encephalomyelitis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Encephalomyelitis, Autoimmune, Experimental
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Endometrial Neoplasms
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Endometrial Neoplasms
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Endometrial Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Endometrial Neoplasms
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Endometriosis
Effects of histone methyltransferase inhibition in endometriosis.
Endometriosis
Inhibition of Histone Methyltransferase EZH2 Suppresses Endometriotic Vesicle Development in a Rat Model of Endometriosis.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Esophageal Squamous Cell Carcinoma
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Foot-and-Mouth Disease
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Friedreich Ataxia
Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
Ganglioglioma
Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with ganglioglioma.
Gastrointestinal Diseases
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Genetic Diseases, Inborn
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Genetic Diseases, Inborn
Kleefstra syndrome: Recurrence in siblings due to a paternal mosaic mutation.
Genetic Diseases, Inborn
Pulmonary hypertension in patients with 9q34.3 microdeletion-associated Kleefstra syndrome.
Glioblastoma
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Glioblastoma
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Glioblastoma
Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma.
Glioblastoma
Novel strategies for molecular targeting to cancer.
Glioblastoma
SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
Glioblastoma
Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
Glioma
A central role for MeCP2 in the epigenetic repression of miR-200c during epithelial-to-mesenchymal transition of glioma.
Glioma
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.
Glioma
Cancer Stem Cells Activate STAT3 the EZ Way.
Glioma
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
Glioma
Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
Glioma
ENHANCER OF ZESTE 2 (EZH2) IS UP-REGULATED IN MALIGNANT GLIOMAS AND IN GLIOMA STEM-LIKE CELLS.
Glioma
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.
Glioma
Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
Glioma
Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity.
Glioma
EZH2-Inhibited MicroRNA-454-3p Promotes M2 Macrophage Polarization in Glioma.
Glioma
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Glioma
Histone methyltransferase SUV39H2 regulates cell growth and chemosensitivity in glioma via regulation of hedgehog signaling.
Glioma
HP1? is highly expressed in glioma cells and facilitates cell proliferation and survival.
Glioma
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Glioma
Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.
Glioma
Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation.
Glioma
SETDB1 in cancer: overexpression and its therapeutic implications.
Glioma
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Glioma
TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
Graft vs Host Disease
Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation.
Graft vs Host Disease
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.
Growth Hormone-Secreting Pituitary Adenoma
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Head and Neck Neoplasms
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
Hearing Loss
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Hearing Loss
Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss.
Heart Defects, Congenital
G9?-dependent histone H3K9me3 hypomethylation promotes overexpression of cardiomyogenesis-related genes in foetal mice.
Heart Defects, Congenital
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Heart Diseases
The promising therapeutic agents for heart diseases: Histone Methyltransferase inhibitors.
Heart Failure
The chromatin-binding protein Smyd1 restricts adult mammalian heart growth.
Heart Failure
The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure.
Hematologic Neoplasms
Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Hematologic Neoplasms
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Hematologic Neoplasms
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Hematologic Neoplasms
The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Hematologic Neoplasms
[Advances of Researches on the Role of Histone Modification in Hematological Neoplasms].
Hepatitis
Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.
Hepatitis B
HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.
Hepatitis B
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Hepatitis B, Chronic
Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population.
Hepatitis B, Chronic
Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study.
Herpes Simplex
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Huntington Disease
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Huntington Disease
Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model.
Huntington Disease
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Hyperalgesia
Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.
Hyperglycemia
High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy.
Hypersensitivity
Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.
Hypersensitivity
Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression.
Hypersensitivity
Histone H3 lysine 36 methyltransferase mobilizes NER factors to regulate tolerance against alkylation damage in fission yeast.
Hypersensitivity
Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack.
Hypersensitivity
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Hypertension
Genomic analysis of the domestication and post-Spanish conquest evolution of the llama and alpaca.
Hypertrichosis
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Hypertrichosis
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Hypogonadism
Hypogonadotropic Hypogonadism and Kleefstra Syndrome due to a Pathogenic Variant in the EHMT1 Gene: An Underrecognized Association.
Hypogonadism
Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells.
Infections
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
Infections
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.
Infections
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Infections
Histone methyltransferase SUV39H1 participates in host defense by methylating mycobacterial histone-like protein HupB.
Infections
Host genetic variants influencing the clinical course of hepatitis B virus infection.
Infections
IFI16, a nuclear innate immune DNA sensor, mediates epigenetic silencing of herpesvirus genomes by its association with H3K9 methyltransferases SUV39H1 and GLP.
Infections
Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
Infections
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Infections
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Infections
SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.
Infections
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Infections
Testosterone response of hepatic gene expression in female mice having acquired testosterone-unresponsive immunity to Plasmodium chabaudi malaria.
Infections
Transcriptional Derepression of the ERVWE1 Locus following Influenza A Virus Infection.
Infertility
A team of heterochromatin factors collaborates with small RNA pathways to combat repetitive elements and germline stress.
Infertility
Prdm9 inter-subspecific interactions in hybrid male sterility of house mouse.
Infertility, Male
PRDM Histone Methyltransferase mRNA Levels Increase in Response to Curative Hormone Treatment for Cryptorchidism-Dependent Male Infertility.
Inflammatory Bowel Diseases
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Inflammatory Bowel Diseases
The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).
Influenza, Human
Transcriptional Derepression of the ERVWE1 Locus following Influenza A Virus Infection.
Insulin Resistance
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex.
Intellectual Disability
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
Intellectual Disability
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Intellectual Disability
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Intellectual Disability
Derepression of inflammation-related genes link to microglia activation and neural maturation defect in a mouse model of Kleefstra syndrome.
Intellectual Disability
Distinct Pathogenic Genes Causing Intellectual Disability and Autism Exhibit a Common Neuronal Network Hyperactivity Phenotype.
Intellectual Disability
EHMT1 regulates Parvalbumin-positive interneuron development and GABAergic input in sensory cortical areas.
Intellectual Disability
Epigenetic regulation in human brain-focus on histone lysine methylation.
Intellectual Disability
Epigenetic regulation of learning and memory by Drosophila EHMT/G9a.
Intellectual Disability
Euchromatin histone methyltransferase 1 regulates cortical neuronal network development.
Intellectual Disability
Exon resequencing of H3K9 methyltransferase complex genes, EHMT1, EHTM2 and WIZ, in Japanese autism subjects.
Intellectual Disability
First episode of psychosis in Kleefstra syndrome: a case report.
Intellectual Disability
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
Intellectual Disability
Haploinsufficiency of EHMT1 improves pattern separation and increases hippocampal cell proliferation.
Intellectual Disability
Hippocampal dysfunction in the Euchromatin histone methyltransferase 1 heterozygous knockout mouse model for Kleefstra syndrome.
Intellectual Disability
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Intellectual Disability
Increased H3K9 methylation and impaired expression of Protocadherins are associated with the cognitive dysfunctions of the Kleefstra syndrome.
Intellectual Disability
Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
Intellectual Disability
Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome.
Intellectual Disability
Reduced exploration, increased anxiety, and altered social behavior: Autistic-like features of euchromatin histone methyltransferase 1 heterozygous knockout mice.
Intellectual Disability
Reversible white matter lesions associated with mutant EHMT1 and Kleefstra syndrome.
Intellectual Disability
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Intellectual Disability
Setd5 haploinsufficiency alters neuronal network connectivity and leads to autistic-like behaviors in mice.
Intellectual Disability
The Object Space Task reveals increased expression of cumulative memory in a mouse model of Kleefstra syndrome.
Intellectual Disability
Transcriptional consequences of 16p11.2 deletion and duplication in mouse cortex and multiplex autism families.
Intestinal Neoplasms
The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.
Ischemic Stroke
The progress of research on histone methylation in ischemic stroke pathogenesis.
Kidney Diseases
Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases.
Kidney Diseases
The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1.
Kidney Neoplasms
Histone Methyltransferase G9a Promotes the Development of Renal Cancer through Epigenetic Silencing of Tumor Suppressor Gene SPINK5.
Lafora Disease
Early-onset Lafora body disease.
Language Development Disorders
Human subtelomeric copy number gains suggest a DNA replication mechanism for formation: beyond breakage-fusion-bridge for telomere stabilization.
Language Disorders
First episode of psychosis in Kleefstra syndrome: a case report.
Leiomyoma
The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
Leukemia
A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
Leukemia
A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival.
Leukemia
An MLL-dependent network sustains hematopoiesis.
Leukemia
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.
Leukemia
ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Leukemia
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.
Leukemia
Clathrin Assembly Lymphoid Myeloid Leukemia-AF10-positive Acute Leukemias: A Report of 2 Cases with a Review of the Literature.
Leukemia
Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro.
Leukemia
Decreased mixed lineage leukemia 1 is involved in endometriosis-related infertility.
Leukemia
Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1.
Leukemia
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
Leukemia
Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.
Leukemia
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Leukemia
Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Leukemia
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
Leukemia
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Leukemia
Dual functions of histone-lysine N-methyltransferase Setdb1 protein at promyelocytic leukemia-nuclear body (PML-NB): maintaining PML-NB structure and regulating the expression of its associated genes.
Leukemia
Elements of the Polycomb repressor SU(Z)12 needed for histone H3-K27 methylation, the interface with E(Z), and in vivo function.
Leukemia
Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Leukemia
Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Leukemia
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
Leukemia
Gene-specific patterns of coregulator requirements by estrogen receptor-? in breast cancer cells.
Leukemia
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
Leukemia
Global and Hox-specific roles for the MLL1 methyltransferase.
Leukemia
H3K9 methyltransferase G9a negatively regulates UHRF1 transcription during leukemia cell differentiation.
Leukemia
Histone Methylation Directs Myeloid TLR4 Expression and Regulates Wound Healing following Cutaneous Tissue Injury.
Leukemia
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Leukemia
Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance.
Leukemia
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Leukemia
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
Leukemia
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
Leukemia
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.
Leukemia
Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation.
Leukemia
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
Leukemia
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Leukemia
Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
Leukemia
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
Leukemia
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Leukemia
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
Leukemia
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Leukemia
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Leukemia
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
Leukemia
lncRNA MIAT promotes cell invasion and migration in esophageal cancer.
Leukemia
Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation.
Leukemia
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis.
Leukemia
Lysine methyltransferase G9a is required for de novo DNA methylation and the establishment, but not the maintenance, of proviral silencing.
Leukemia
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
Leukemia
MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.
Leukemia
Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Leukemia
MicroRNAs mark in the MLL-rearranged leukemia.
Leukemia
Misguided transcriptional elongation causes mixed lineage leukemia.
Leukemia
Mixed Lineage Leukemia 1 Promoted Neuron Apoptosis in Ischemic Penumbra via Regulating ASK-1/TNF-? Complex.
Leukemia
Mixed-lineage leukemia protein 2 suppresses ciliary assembly by the modulation of actin dynamics and vesicle transport.
Leukemia
MLL translocation in two castration-resistant prostate cancer patients.
Leukemia
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Leukemia
MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
Leukemia
MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-?B signaling pathway via H3K4me3 enrichment in the TLR4 promoter region.
Leukemia
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
Leukemia
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Leukemia
MLL: a histone methyltransferase disrupted in leukemia.
Leukemia
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Leukemia
NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1.
Leukemia
Negative Regulation of JAK2 by H3K9 Methyltransferase G9a in Leukemia.
Leukemia
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Leukemia
Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
Leukemia
Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of
Leukemia
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Leukemia
PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity.
Leukemia
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Leukemia
Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters.
Leukemia
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Leukemia
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Leukemia
Regulated nuclear entry of over-expressed Setdb1.
Leukemia
Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk.
Leukemia
ROR? autoregulates its transcription via MLL4-associated enhancer remodeling in the liver.
Leukemia
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Leukemia
SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Leukemia
SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ?Np63? protein.
Leukemia
Solution NMR structure and histone binding of the PHD domain of human MLL5.
Leukemia
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Leukemia
Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Leukemia
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Leukemia
SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90.
Leukemia
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Leukemia
Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Leukemia
Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.
Leukemia
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Leukemia
The epigenetic control of E-box and Myc-dependent chromatin modifications regulate the licensing of lamin B2 origin during cell cycle.
Leukemia
The Histone Methyltransferase DOT1L Is Essential for Humoral Immune Responses.
Leukemia
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Leukemia
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Leukemia
The Histone Methyltransferase Mixed Lineage Leukemia (MLL) 3 May Play a Potential Role on Clinical Dilated Cardiomyopathy.
Leukemia
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Leukemia
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Leukemia
The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes.
Leukemia
The STAT4/MLL1 Epigenetic Axis Regulates the Antimicrobial Functions of Murine Macrophages.
Leukemia
Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
Leukemia
[Effect of SUV39H1 siRNA Silence on Apoptosis and Proliferation of Acute Myelogenous Leukemia KG-1 Cell Line].
Leukemia
[Experimental study of SUV39H1 gene specific siRNA in human leukemia cell line].
Leukemia, Erythroblastic, Acute
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
Leukemia, Erythroblastic, Acute
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.
Leukemia, Erythroblastic, Acute
The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture.
Leukemia, Lymphocytic, Chronic, B-Cell
Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation.
Leukemia, Lymphocytic, Chronic, B-Cell
Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Leukemia, Mast-Cell
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Leukemia, Myeloid
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Leukemia, Myeloid
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Leukemia, Myeloid
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
Leukemia, Myeloid
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
Leukemia, Myeloid, Acute
---Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia-.
Leukemia, Myeloid, Acute
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Leukemia, Myeloid, Acute
Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
Leukemia, Myeloid, Acute
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Leukemia, Myeloid, Acute
Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Leukemia, Myeloid, Acute
Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Leukemia, Myeloid, Acute
PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells.
Leukemia, Myeloid, Acute
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Leukemia, Myeloid, Acute
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Leukemia, Myeloid, Acute
SETDB1 in cancer: overexpression and its therapeutic implications.
Leukemia, Myeloid, Acute
SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Leukemia, Myeloid, Acute
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Leukemia, Myeloid, Acute
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Leukemia, Myeloid, Acute
Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
Leukemia, Myeloid, Acute
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Leukemia, Myeloid, Acute
The NIZP1 KRAB and C2HR domains cross-talk for transcriptional regulation.
Leukemia, Myeloid, Acute
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
[Effect of SUV39H1 siRNA Silence on Apoptosis and Proliferation of Acute Myelogenous Leukemia KG-1 Cell Line].
Liver Cirrhosis
A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.
Liver Cirrhosis
A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma.
Liver Neoplasms
Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Liver Neoplasms
Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Liver Neoplasms
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Liver Neoplasms
Inactivation of lncRNA HOTAIRM1 caused by histone methyltransferase RIZ1 accelerated the proliferation and invasion of liver cancer.
Liver Neoplasms
Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis.
Liver Neoplasms
miR24-2 accelerates progression of liver cancer cells by activating Pim1 through tri-methylation of Histone H3 on the ninth lysine.
Liver Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Lung Injury
Inhibition of EZH2 prevents acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis by regulating the macrophage polarization phenotype.
Lung Neoplasms
A regulatory circuitry comprising TP53, miR-29 family, and SETDB1 in non-small cell lung cancer.
Lung Neoplasms
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Lung Neoplasms
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Lung Neoplasms
Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death.
Lung Neoplasms
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Lung Neoplasms
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Lung Neoplasms
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Lung Neoplasms
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Lung Neoplasms
Elevated Metabolic Activity on (18)F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
Lung Neoplasms
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Lung Neoplasms
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Lung Neoplasms
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Lung Neoplasms
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
Lung Neoplasms
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
Lung Neoplasms
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
Lung Neoplasms
Histone methyltransferase SETD1A participates in lung cancer progression.
Lung Neoplasms
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Lung Neoplasms
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
Lung Neoplasms
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
Lung Neoplasms
Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
Lung Neoplasms
Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294.
Lung Neoplasms
Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer.
Lung Neoplasms
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lung Neoplasms
S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility.
Lung Neoplasms
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
Lung Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Lung Neoplasms
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Lung Neoplasms
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Lung Neoplasms
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
Lung Neoplasms
The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Lung Neoplasms
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Lung Neoplasms
Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.
Lymphatic Metastasis
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Lymphatic Metastasis
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Lymphatic Metastasis
High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan.
Lymphatic Metastasis
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Lymphatic Metastasis
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Lymphatic Metastasis
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Lymphoma
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type is associated with disease progression and prognosis.
Lymphoma
Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.
Lymphoma
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Lymphoma
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Lymphoma
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Lymphoma
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Lymphoma
EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Lymphoma
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Lymphoma
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Lymphoma
Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Lymphoma
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Lymphoma
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Lymphoma
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Lymphoma, B-Cell
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Lymphoma, B-Cell
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Lymphoma, B-Cell
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Lymphoma, B-Cell
Deregulation of H3K27 methylation in cancer.
Lymphoma, B-Cell
EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells.
Lymphoma, B-Cell
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Lymphoma, B-Cell
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
Lymphoma, B-Cell
Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Lymphoma, B-Cell
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Lymphoma, B-Cell
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Lymphoma, B-Cell
The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Lymphoma, B-Cell
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, B-Cell
Treating lymphoma is now a bit EZ-er.
Lymphoma, Follicular
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Lymphoma, Follicular
EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Lymphoma, Follicular
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Lymphoma, Follicular
Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Lymphoma, Follicular
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Large B-Cell, Diffuse
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Lymphoma, Large B-Cell, Diffuse
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Lymphoma, Large B-Cell, Diffuse
Deregulation of H3K27 methylation in cancer.
Lymphoma, Large B-Cell, Diffuse
EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells.
Lymphoma, Large B-Cell, Diffuse
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Large B-Cell, Diffuse
Treating lymphoma is now a bit EZ-er.
Lymphoma, Large-Cell, Anaplastic
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Lymphoma, Mantle-Cell
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Lymphoma, Non-Hodgkin
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Lymphoma, Non-Hodgkin
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma.
Lymphoma, Non-Hodgkin
Studies Identify Non-Hodgkin Lymphoma Suppressor.
Lymphoma, T-Cell
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Lymphoma, T-Cell
Oncogene-induced senescence as an initial barrier in lymphoma development.
Lymphopenia
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Malaria
A histone methyltransferase inhibitor can reverse epigenetically acquired drug resistance in the malaria parasite Plasmodium falciparum.
Malaria
Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans.
Malaria
The Role of the Histone Methyltransferase PfSET10 in Antigenic Variation by Malaria Parasites: a Cautionary Tale.
Mastocytosis
Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells: Implications for Mastocytosis.
Medulloblastoma
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Medulloblastoma
Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
Medulloblastoma
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.
Melanoma
A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
Melanoma
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Melanoma
Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11.
Melanoma
BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases.
Melanoma
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.
Melanoma
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
Melanoma
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Melanoma
EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Melanoma
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Melanoma
G9a Is SETting the Stage for Colorectal Oncogenesis.
Melanoma
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Melanoma
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.
Melanoma
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Melanoma
High frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.
Melanoma
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Melanoma
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Melanoma
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Melanoma
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Melanoma
Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression.
Melanoma
Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma.
Melanoma
Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.
Melanoma
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Melanoma
SETDB1 in cancer: overexpression and its therapeutic implications.
Melanoma
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Melanoma
SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.
Melanoma
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.
Meningioma
The transducible TAT-RIZ1-PR protein exerts histone methyltransferase activity and tumor-suppressive functions in human malignant meningiomas.
Mesothelioma
CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition.
Mesothelioma
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Mesothelioma
Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mesothelioma
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Mesothelioma
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Mesothelioma, Malignant
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Microcephaly
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
Movement Disorders
Variants in estrogen-related genes and risk of Parkinson's disease.
Multiple Endocrine Neoplasia
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Multiple Endocrine Neoplasia Type 1
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Multiple Myeloma
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Multiple Myeloma
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma.
Multiple Myeloma
EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Multiple Myeloma
H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.
Multiple Myeloma
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Multiple Myeloma
Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
Multiple Myeloma
Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
Multiple Myeloma
Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis.
Multiple Myeloma
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Multiple Myeloma
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Multiple Myeloma
NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.
Multiple Myeloma
The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.
Multiple Myeloma
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Multiple Myeloma
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Multiple Myeloma
Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Multiple Sclerosis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Muscle Hypotonia
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
Muscle Hypotonia
First episode of psychosis in Kleefstra syndrome: a case report.
Muscle Hypotonia
Reduced Euchromatin histone methyltransferase 1 causes developmental delay, hypotonia, and cranial abnormalities associated with increased bone gene expression in Kleefstra syndrome mice.
Muscle Hypotonia
Reversible white matter lesions associated with mutant EHMT1 and Kleefstra syndrome.
Muscular Dystrophies
FSHD muscular dystrophy region gene 1 binds Suv4-20h1 histone methyltransferase and impairs myogenesis.
Myelodysplastic Syndromes
Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2).
Myelodysplastic Syndromes
Decreased expression of PRDM2 (RIZ1) and its correlation with risk stratification in patients with myelodysplastic syndrome.
Myelodysplastic Syndromes
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Myelodysplastic Syndromes
RNA splicing, cell signaling, and response to therapies.
Myelodysplastic Syndromes
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Myelodysplastic Syndromes
The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Myocardial Infarction
Role of Muscle-Specific Histone Methyltransferase (Smyd1) in Exercise-Induced Cardioprotection against Pathological Remodeling after Myocardial Infarction.
Myocardial Infarction
The combination of G9a histone methyltransferase inhibitors with erythropoietin protects heart against damage from acute myocardial infarction.
Myocardial Infarction
The histone H3K9 methyltransferase SUV39H links SIRT1 repression to myocardial infarction.
Myocardial Ischemia
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
Nasopharyngeal Carcinoma
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
SETDB1 in cancer: overexpression and its therapeutic implications.
Neoplasm Metastasis
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Neoplasm Metastasis
A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
Neoplasm Metastasis
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Neoplasm Metastasis
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Neoplasm Metastasis
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Neoplasm Metastasis
BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.
Neoplasm Metastasis
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Neoplasm Metastasis
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Neoplasm Metastasis
Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis-more than one way to skin a cat.
Neoplasm Metastasis
DZNep inhibits Hif-1? and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.
Neoplasm Metastasis
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Neoplasm Metastasis
EHMT2 is a metastasis regulator in breast cancer.
Neoplasm Metastasis
Emerging role of SETDB1 as a therapeutic target.
Neoplasm Metastasis
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Neoplasm Metastasis
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
Neoplasm Metastasis
G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner.
Neoplasm Metastasis
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Neoplasm Metastasis
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Neoplasm Metastasis
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Neoplasm Metastasis
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
Neoplasm Metastasis
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Neoplasm Metastasis
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
Neoplasm Metastasis
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
Neoplasm Metastasis
High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan.
Neoplasm Metastasis
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Neoplasm Metastasis
Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b.
Neoplasm Metastasis
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Neoplasm Metastasis
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Neoplasm Metastasis
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Neoplasm Metastasis
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Neoplasm Metastasis
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Neoplasm Metastasis
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.
Neoplasm Metastasis
LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1 complex.
Neoplasm Metastasis
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
Neoplasm Metastasis
MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Neoplasm Metastasis
Novel strategies for molecular targeting to cancer.
Neoplasm Metastasis
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
Neoplasm Metastasis
Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Neoplasm Metastasis
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
Neoplasm Metastasis
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Neoplasm Metastasis
Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
Neoplasm Metastasis
Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
Neoplasm Metastasis
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Neoplasm Metastasis
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
Neoplasm Metastasis
SETDB1 induces epithelial?mesenchymal transition in breast carcinoma by directly binding with Snail promoter.
Neoplasm Metastasis
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Neoplasm Metastasis
SETDB1 regulates SMAD7 expression for breast cancer metastasis.
Neoplasm Metastasis
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT.
Neoplasm Metastasis
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
Neoplasm Metastasis
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Neoplasm Metastasis
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Neoplasm Metastasis
The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Neoplasm Metastasis
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
Neoplasm Metastasis
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.
Neoplasm Metastasis
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Neoplasm Metastasis
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Neoplasm Metastasis
The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Neoplasm Metastasis
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Neoplasms
---Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia-.
Neoplasms
20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Neoplasms
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Neoplasms
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Neoplasms
5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.
Neoplasms
?Np63? modulates histone methyl transferase SETDB1 to transcriptionally repress target genes in cancers.
Neoplasms
A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
Neoplasms
A dimeric state for PRC2.
Neoplasms
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Neoplasms
A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene.
Neoplasms
A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.
Neoplasms
A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.
Neoplasms
A Systematic Pan-Cancer Analysis of Genetic Heterogeneity Reveals Associations with Epigenetic Modifiers.
Neoplasms
A TGF-?-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis.
Neoplasms
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type is associated with disease progression and prognosis.
Neoplasms
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
Neoplasms
AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions.
Neoplasms
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.
Neoplasms
An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
Neoplasms
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Neoplasms
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Neoplasms
Analysis of somatic microsatellite indels identifies driver events in human tumors.
Neoplasms
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Neoplasms
ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2.
Neoplasms
Anticancer agents: Allosteric histone methyltransferase modulators block tumour growth.
Neoplasms
Arsenic and benzo[a]pyrene co-exposure acts synergistically in inducing cancer stem cell-like property and tumorigenesis by epigenetically down-regulating SOCS3 expression.
Neoplasms
Assignment of a novel bifurcated SET domain gene, SETDB1, to human chromosome band 1q21 by in situ hybridization and radiation hybrids.
Neoplasms
Association of an miR-502-binding site polymorphism in the 3'-untranslated region of SET8 with colorectal cancer.
Neoplasms
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months.
Neoplasms
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Neoplasms
Biochemical Assay Development for Histone Methyltransferases Using a Transcreener-Based Assay for S-Adenosylhomocysteine.
Neoplasms
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
Neoplasms
BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression.
Neoplasms
BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.
Neoplasms
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
Neoplasms
Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies.
Neoplasms
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Neoplasms
Cancer cells, on your histone marks, get SETDB1, silence retrotransposons, and go!
Neoplasms
Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Neoplasms
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Neoplasms
Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.
Neoplasms
Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
Neoplasms
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Neoplasms
Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Neoplasms
Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
Neoplasms
Clinicopathological significance of G9A expression in colorectal carcinoma.
Neoplasms
Combining epigenetic and immune therapy to overcome cancer resistance.
Neoplasms
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Neoplasms
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Neoplasms
Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Neoplasms
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Neoplasms
CRISPR/Cas9 mediated generation of a iPSC line EHTJUi005-A-1 with homozygous knockout of the SUV39H1 gene.
Neoplasms
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
Neoplasms
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Neoplasms
Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability.
Neoplasms
Deficiency of G9a Inhibits Cell Proliferation and Activates Autophagy via Transcriptionally Regulating c-Myc Expression in Glioblastoma.
Neoplasms
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Neoplasms
Depletion of G9a gene induces cell apoptosis in human gastric carcinoma.
Neoplasms
Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death.
Neoplasms
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Neoplasms
Differential expression of selected histone modifier genes in human solid cancers.
Neoplasms
Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Neoplasms
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.
Neoplasms
DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity.
Neoplasms
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Neoplasms
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Neoplasms
Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.
Neoplasms
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells.
Neoplasms
Dual epigenetic modifiers for cancer therapy.
Neoplasms
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Neoplasms
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Neoplasms
DZNep inhibits Hif-1? and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.
Neoplasms
E4BP4/NFIL3 modulates the epigenetically repressed Ras effector RASSF8 function through histone methyl transferases.
Neoplasms
Effects of histone methyltransferase inhibition in endometriosis.
Neoplasms
Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.
Neoplasms
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Neoplasms
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Neoplasms
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Neoplasms
EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
Neoplasms
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
Neoplasms
EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Neoplasms
Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
Neoplasms
Emerging role of SETDB1 as a therapeutic target.
Neoplasms
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Neoplasms
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
Neoplasms
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Neoplasms
Enhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation.
Neoplasms
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Neoplasms
Epidrugs in the immunotherapy of cutaneous and uveal melanoma.
Neoplasms
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer.
Neoplasms
Epigenetic perspective into head and neck cancer through in silico gene expression profiling of histone lysine methyltransferases.
Neoplasms
Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Neoplasms
Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.
Neoplasms
Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma.
Neoplasms
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Neoplasms
Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
Neoplasms
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.
Neoplasms
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Neoplasms
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Neoplasms
Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Neoplasms
Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2.
Neoplasms
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.
Neoplasms
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c.
Neoplasms
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Neoplasms
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Neoplasms
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
Neoplasms
EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Neoplasms
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene.
Neoplasms
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Neoplasms
EZH2, an epigenetic driver of prostate cancer.
Neoplasms
EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin.
Neoplasms
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Neoplasms
EZH2: a pivotal regulator in controlling cell differentiation.
Neoplasms
EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Neoplasms
Fine-tuning AKT kinase activity through direct lysine methylation.
Neoplasms
First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Neoplasms
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
Neoplasms
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
Neoplasms
Functional regulation of hypoxia inducible factor-1? by SET9 lysine methyltransferase.
Neoplasms
Functional Role of G9a Histone Methyltransferase in Cancer.
Neoplasms
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Neoplasms
G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.
Neoplasms
G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner.
Neoplasms
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
Neoplasms
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Neoplasms
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Neoplasms
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
Neoplasms
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Neoplasms
Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Neoplasms
Genome-wide screening and functional analysis identifies tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma.
Neoplasms
Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation.
Neoplasms
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Neoplasms
Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
Neoplasms
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
Neoplasms
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
Neoplasms
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
Neoplasms
H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression.
Neoplasms
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.
Neoplasms
High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
Neoplasms
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Neoplasms
High WHSC1L1 Expression Reduces Survival Rates in Operated Breast Cancer Patients with Decreased CD8+ T Cells: Machine Learning Approach.
Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Neoplasms
Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Neoplasms
Histone H3K4 methyltransferase Mll1 regulates protein glycosylation and tunicamycin-induced apoptosis through transcriptional regulation.
Neoplasms
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Neoplasms
Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b.
Neoplasms
Histone methyltransferase and drug resistance in cancers.
Neoplasms
Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function.
Neoplasms
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Neoplasms
Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Neoplasms
Histone Methyltransferase G9a Promotes the Development of Renal Cancer through Epigenetic Silencing of Tumor Suppressor Gene SPINK5.
Neoplasms
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Neoplasms
Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Neoplasms
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.
Neoplasms
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Neoplasms
Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance.
Neoplasms
Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Neoplasms
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Neoplasms
Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Neoplasms
Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Neoplasms
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Neoplasms
Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Neoplasms
Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation through the STAT1-CCND1/CDK6 Axis.
Neoplasms
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Neoplasms
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Neoplasms
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Neoplasms
Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Neoplasms
Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.
Neoplasms
Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells.
Neoplasms
Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
Neoplasms
Identification of druggable cancer driver genes amplified across TCGA datasets.
Neoplasms
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Neoplasms
Identification of PRDM2 regulated genes in quiescent C2C12 myoblasts.
Neoplasms
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Neoplasms
Identification of somatic mutations in parathyroid tumors using whole-exome sequencing.
Neoplasms
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Neoplasms
Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features.
Neoplasms
Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.
Neoplasms
Impaired IRE1 expression and XBP1 activation is a hallmark of GCB-DLBCL and contributes to tumor growth.
Neoplasms
Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
Neoplasms
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
Neoplasms
In vivo administration of G9a inhibitor A366 decreases osteogenic potential of bone marrow-derived mesenchymal stem cells.
Neoplasms
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Neoplasms
Inactivation of a histone methyltransferase by mutations in human cancers.
Neoplasms
Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks.
Neoplasms
Increased expression of G9A contributes to carcinogenesis and indicates poor prognosis in hepatocellular carcinoma.
Neoplasms
Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.
Neoplasms
Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-?B.
Neoplasms
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Neoplasms
Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.
Neoplasms
Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.
Neoplasms
Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis.
Neoplasms
Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
Neoplasms
Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.
Neoplasms
Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer.
Neoplasms
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Neoplasms
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Neoplasms
Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
Neoplasms
Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance.
Neoplasms
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Neoplasms
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Neoplasms
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Neoplasms
Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.
Neoplasms
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Neoplasms
Knockout of SETDB1 gene using the CRISPR/cas-9 system increases migration and transforming activities via complex regulations of E-cadherin, ?-catenin, STAT3, and Akt.
Neoplasms
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
Neoplasms
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
Neoplasms
LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma.
Neoplasms
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Neoplasms
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Neoplasms
Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics.
Neoplasms
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Neoplasms
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Neoplasms
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
Neoplasms
Metallothionein 1h Tumor Suppressor Activity in Prostate Cancer Is Mediated By Euchromatin Methyltransferase 1.
Neoplasms
Metformin inhibits SUV39H1-mediated migration of prostate cancer cells.
Neoplasms
Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis.
Neoplasms
Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability.
Neoplasms
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
Neoplasms
MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.
Neoplasms
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Neoplasms
MLL1 promotes cervical carcinoma cell tumorigenesis and metastasis through interaction with ?-catenin.
Neoplasms
MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication.
Neoplasms
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Neoplasms
Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.
Neoplasms
Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis.
Neoplasms
MUC1-C activates EZH2 expression and function in human cancer cells.
Neoplasms
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Neoplasms
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Neoplasms
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Neoplasms
Mutation of cancer driver MLL2 results in transcription stress and genome instability.
Neoplasms
Myc, Cdk2 and cellular senescence: Old players, new game.
Neoplasms
Negative regulation of DAB2IP by Akt and SCFFbw7 pathways.
Neoplasms
NNK-induced DNA methyltransferase 1 in lung tumorigenesis in A/J mice and inhibitory effects of (-)-epigallocatechin-3-gallate.
Neoplasms
Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Neoplasms
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
Neoplasms
NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression.
Neoplasms
NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates.
Neoplasms
Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines.
Neoplasms
Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
Neoplasms
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Neoplasms
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Neoplasms
Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Neoplasms
Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
Neoplasms
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage.
Neoplasms
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Neoplasms
Polycomb repressive complex 2 contributes to DNA double-strand break repair.
Neoplasms
Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
Neoplasms
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
Neoplasms
Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
Neoplasms
Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome.
Neoplasms
Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.
Neoplasms
Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
Neoplasms
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Neoplasms
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Neoplasms
Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Neoplasms
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Neoplasms
Promiscuous RNA binding by Polycomb repressive complex 2.
Neoplasms
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Neoplasms
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
Neoplasms
Proteomic and functional genomic landscape of receptor tyrosine kinase and ras to extracellular signal-regulated kinase signaling.
Neoplasms
Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells.
Neoplasms
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.
Neoplasms
Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model.
Neoplasms
Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.
Neoplasms
Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression.
Neoplasms
Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.
Neoplasms
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Neoplasms
Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Neoplasms
Regulation of the DNA Damage Response and Gene Expression by the Dot1L Histone Methyltransferase and the 53Bp1 Tumour Suppressor.
Neoplasms
RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.
Neoplasms
RNA interference targeting against S100A4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells.
Neoplasms
Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation.
Neoplasms
Role of STAT3 and Vitamin D Receptor in EZH2-mediated invasion of human colorectal cancer.
Neoplasms
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Neoplasms
Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Neoplasms
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Neoplasms
Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF.
Neoplasms
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
Neoplasms
SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma.
Neoplasms
SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
Neoplasms
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
Neoplasms
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Neoplasms
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Neoplasms
SETDB1 modulates the differentiation of both the crystal cells and the lamellocytes in Drosophila.
Neoplasms
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Neoplasms
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Neoplasms
SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
Neoplasms
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
Neoplasms
SETDB1-Mediated Silencing of Retroelements.
Neoplasms
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
Neoplasms
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
Neoplasms
Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma.
Neoplasms
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.
Neoplasms
Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls
Neoplasms
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
Neoplasms
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Neoplasms
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Neoplasms
SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.
Neoplasms
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Neoplasms
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Neoplasms
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Neoplasms
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT.
Neoplasms
Structural and Functional Characterization of the Acidic Region from the RIZ Tumor Suppressor.
Neoplasms
Structural basis for PRC2 engagement with chromatin.
Neoplasms
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Neoplasms
Structures of Nahuoic Acids B-E Produced in Culture by a Streptomyces sp. Isolated from a Marine Sediment and Evidence for the Inhibition of the Histone Methyl Transferase SETD8 in Human Cancer Cells by Nahuoic Acid A.
Neoplasms
Studies Identify Non-Hodgkin Lymphoma Suppressor.
Neoplasms
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
Neoplasms
Surveillance of Retroelement Expression and Nucleic-Acid Immunity by Histone Methyltransferase SETDB1.
Neoplasms
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
Neoplasms
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
Neoplasms
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Neoplasms
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
Neoplasms
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Neoplasms
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Neoplasms
Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Neoplasms
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Neoplasms
Targeting epigenetic machinery: Emerging novel allosteric inhibitors.
Neoplasms
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Neoplasms
Targeting FBXO44/SUV39H1 elicits tumor cell-specific DNA replication stress and viral mimicry.
Neoplasms
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Neoplasms
Targeting histone methyltransferase EZH2 as cancer treatment.
Neoplasms
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
Neoplasms
Targeting of cyclin-dependent kinases in atypical teratoid rhabdoid tumors with multikinase inhibitor TG02.
Neoplasms
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
Neoplasms
Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity.
Neoplasms
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Neoplasms
TERT promoter mutations in primary liver tumors.
Neoplasms
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Neoplasms
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Neoplasms
The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2,4-Diamino-7-aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies.
Neoplasms
The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
Neoplasms
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
Neoplasms
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.
Neoplasms
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Neoplasms
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Neoplasms
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Neoplasms
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Neoplasms
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.
Neoplasms
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Neoplasms
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Neoplasms
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Neoplasms
The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors.
Neoplasms
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Neoplasms
The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
Neoplasms
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Neoplasms
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1? Stability and Angiogenesis.
Neoplasms
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Neoplasms
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Neoplasms
The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells.
Neoplasms
The Histone Methyltransferase Smyd2 Is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor ? (TNF-?) Production.
Neoplasms
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Neoplasms
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Neoplasms
The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.
Neoplasms
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Neoplasms
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
Neoplasms
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
Neoplasms
The methylation profiles of PRDM promoters in non-small cell lung cancer.
Neoplasms
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.
Neoplasms
The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
Neoplasms
The polycomb group protein EZH2 is a novel therapeutic target for cervical cancer.
Neoplasms
The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.
Neoplasms
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
Neoplasms
The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.
Neoplasms
The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2.
Neoplasms
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Neoplasms
The Role of G9a in Tumorigenesis in Head and Neck Cancer.
Neoplasms
The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
Neoplasms
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Neoplasms
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.
Neoplasms
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.
Neoplasms
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis.
Neoplasms
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Neoplasms
Toward a Consensus on the Binding Specificity and Promiscuity of PRC2 for RNA.
Neoplasms
Transcription analysis of a histones modifiers panel coupled with critical tumor suppressor genes displayed frequent changes in patients with AML.: mRNA levels of histones modifiers and TSGs in AML.
Neoplasms
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Neoplasms
Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.
Neoplasms
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Neoplasms
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Neoplasms
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Neoplasms
Using S-adenosyl-L-homocysteine capture compounds to characterize S-adenosyl-L-methionine and S-adenosyl-L-homocysteine binding proteins.
Neoplasms
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Neoplasms
Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.
Neoplasms
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Neoplasms
Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Neoplasms
Whole-exome sequencing identifies variants in invasive pituitary adenomas.
Neoplasms
Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers.
Neoplasms
Wolf-Hirschhorn syndrome candidate 1 facilitates alveolar macrophage pyroptosis in sepsis-induced acute lung injury through NEK7-mediated NLRP3 inflammasome activation.
Neoplasms
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Neoplasms
[An update on epigenetic regulator gene mutations and pathogenesis of myelodysplasic syndromes].
Neoplasms
[Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]
Neoplasms
[The significance of histone modifications in malignant transformation].
Neoplasms, Germ Cell and Embryonal
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
Neoplasms, Squamous Cell
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Nervous System Diseases
Structural and functional annotation of PR/SET Domain (PRDM) protein family: In-silico study elaborating role of PRDM12 mutation in congenital insensitivity to pain.
Neuralgia
Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression.
Neuralgia
Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain.
Neuralgia
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Neuroblastoma
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
Neuroblastoma
Correction: Inhibition of H3K9 Methyltransferase G9a Repressed Cell Proliferation and Induced Autophagy in Neuroblastoma Cells.
Neuroblastoma
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Neuroblastoma
Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Neuroblastoma
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.
Neuroblastoma
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Neuroblastoma
Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma.
Neuroblastoma
Inhibition of H3K9 methyltransferase G9a repressed cell proliferation and induced autophagy in neuroblastoma cells.
Neuroblastoma
Oxidative stress-induced aberrant G9a activation disturbs RE-1-containing neuron-specific genes expression, leading to degeneration in human SH-SY5Y neuroblastoma cells.
Neuroblastoma
Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells.
Neuroblastoma
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Non-alcoholic Fatty Liver Disease
The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice.
Obesity
ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Obesity
Correction to: ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Obesity
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex.
Obesity
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Obesity
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Obesity
The Histone Methyltransferase MLL1 Directs Macrophage-Mediated Inflammation in Wound Healing and Is Altered in a Murine Model of Obesity and Type 2 Diabetes.
Osteoarthritis
Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis.
Osteoarthritis
EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis.
Osteoarthritis
The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/?-catenin pathway.
Osteoporosis
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis.
Osteosarcoma
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.
Osteosarcoma
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
Osteosarcoma
Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/?-catenin signaling.
Osteosarcoma
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Osteosarcoma
Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma.
Osteosarcoma
Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.
Osteosarcoma
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.
Osteosarcoma
SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma.
Osteosarcoma
Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.
Ovarian Neoplasms
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Ovarian Neoplasms
Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells.
Ovarian Neoplasms
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Ovarian Neoplasms
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Ovarian Neoplasms
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Ovarian Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Ovarian Neoplasms
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Ovarian Neoplasms
Ketamine Inhibits Ovarian Cancer Cell Growth by Regulating the lncRNA-PVT1/EZH2/p57 Axis.
Ovarian Neoplasms
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Ovarian Neoplasms
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Ovarian Neoplasms
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Ovarian Neoplasms
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Ovarian Neoplasms
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Pancreatic Neoplasms
Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.
Pancreatic Neoplasms
S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility.
Pancreatic Neoplasms
SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.
Pancreatic Neoplasms
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Parkinson Disease
Variants in estrogen-related genes and risk of Parkinson's disease.
Peritoneal Fibrosis
Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis.
Persistent Infection
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection.
Pituitary Neoplasms
Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.
Pituitary Neoplasms
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Prader-Willi Syndrome
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Prader-Willi Syndrome
Reactivation of maternal SNORD116 cluster via SETDB1 knockdown in Prader-Willi syndrome iPSCs.
Prader-Willi Syndrome
Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center.
Prader-Willi Syndrome
Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epigenetic approaches in glioblastoma multiforme and their implication in screening and diagnosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Progeria
Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model.
Prolactinoma
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature.
Prostatic Hyperplasia
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Prostatic Neoplasms
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Prostatic Neoplasms
Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
Prostatic Neoplasms
EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
Prostatic Neoplasms
EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.
Prostatic Neoplasms
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
Prostatic Neoplasms
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Prostatic Neoplasms
EZH2, an epigenetic driver of prostate cancer.
Prostatic Neoplasms
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Prostatic Neoplasms
Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Prostatic Neoplasms
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.
Prostatic Neoplasms
Histone Methyltransferase Setd7 Regulates Nrf2 Signaling Pathway by Phenethyl Isothiocyanate and Ursolic Acid in Human Prostate Cancer Cells.
Prostatic Neoplasms
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Prostatic Neoplasms
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Prostatic Neoplasms
Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation.
Prostatic Neoplasms
Identification of Differentially Methylated Regions Associated with a Knockout of SUV39H1 in Prostate Cancer Cells.
Prostatic Neoplasms
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
Prostatic Neoplasms
Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
Prostatic Neoplasms
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Prostatic Neoplasms
Novel strategies for molecular targeting to cancer.
Prostatic Neoplasms
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Prostatic Neoplasms
Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
Prostatic Neoplasms
Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription.
Prostatic Neoplasms
SETDB1 in cancer: overexpression and its therapeutic implications.
Prostatic Neoplasms
SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells.
Prostatic Neoplasms
Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Prostatic Neoplasms
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Prostatic Neoplasms
The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or SiRNA Demonstrates Its Involvement in MGMT, TRA2A, RPS6KA2, and U2AF1 Gene Regulation in Prostate Cancer.
Prostatic Neoplasms
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Prostatic Neoplasms
Transcriptomic Analysis of Histone Methyltransferase Setd7 Knockdown and Phenethyl Isothiocyanate in Human Prostate Cancer Cells.
Prostatic Neoplasms
Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells.
Pseudorabies
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
Psoriasis
Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris.
Pulmonary Disease, Chronic Obstructive
An efficient hybrid feature selection method to identify potential biomarkers in common chronic lung inflammatory diseases.
Pulmonary Disease, Chronic Obstructive
Corrigendum: SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.
Pulmonary Disease, Chronic Obstructive
SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.
Reperfusion Injury
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
Reperfusion Injury
Suv39h1 protects from myocardial ischemia-reperfusion injury in diabetic rats.
Reperfusion Injury
The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1.
Retinoblastoma
Diverse roles of WDR5-RbBP5-ASH2L-DPY30 (WRAD) complex in the functions of the SET1 histone methyltransferase family.
Retinoblastoma
Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.
Retinoblastoma
Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics.
Retinoblastoma
Rb targets histone H3 methylation and HP1 to promoters.
Retinoblastoma
Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase.
Rhabdoid Tumor
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Rhabdomyosarcoma, Alveolar
Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.
Rhabdomyosarcoma, Alveolar
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.
Rhabdomyosarcoma, Alveolar
Stuck in a balancing act: histone methyltransferase activity of KMT1A traps alveolar rhabdomyosarcomas in an undifferentiated state.
Rhabdomyosarcoma, Alveolar
The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
Rhabdomyosarcoma, Embryonal
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.
Rheumatic Diseases
EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis.
Sarcoma
Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
Sarcoma
Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Sarcoma, Ewing
Identification of driver genes associated with chemotherapy resistance of Ewing's sarcoma.
Scleroderma, Systemic
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
Scoliosis
Suv39h1 promotes facet joint chondrocyte proliferation by targeting miR-15a/Bcl2 in idiopathic scoliosis patients.
Sepsis
Dynamic and selective nucleosome repositioning during endotoxin tolerance.
Sepsis
Inhibition of EZH2 prevents acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis by regulating the macrophage polarization phenotype.
Sepsis
Lymphocyte expression of EZH2 is associated with mortality and secondary infectious complications in sepsis.
Sepsis
Novel pharmacological inhibition of EZH2 attenuates septic shock by altering innate inflammatory responses to sepsis.
Severe Acute Respiratory Syndrome
Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.
Skin Neoplasms
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Small Cell Lung Carcinoma
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Sotos Syndrome
19p13.2 microduplication causes a Sotos syndrome-like phenotype and alters gene expression.
Sotos Syndrome
Co-occurrence of a maternally inherited DNMT3A duplication and a paternally inherited pathogenic variant in EZH2 in a child with growth retardation and severe short stature: atypical Weaver syndrome or evidence of a DNMT3A dosage effect?
Sotos Syndrome
Decreased serum dependence in the growth of NIH3T3 cells from the overexpression of human nuclear receptor-binding SET-domain-containing protein 1 (NSD1) or fission yeast su(var)3-9, enhancer-of-zeste, trithorax 2 (SET2).
Sotos Syndrome
Disrupted epigenetics in the Sotos syndrome neurobehavioral phenotype.
Sotos Syndrome
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging.
Sotos Syndrome
Hypoparathyroidism in a 3-year-old Korean boy with Sotos syndrome and a novel mutation in NSD1.
Sotos Syndrome
Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1.
Sotos Syndrome
NSD1 mutations generate a genome-wide DNA methylation signature.
Sotos Syndrome
Screening for genes that accelerate the epigenetic aging clock in humans reveals a role for the H3K36 methyltransferase NSD1.
Sotos Syndrome
Sotos syndrome.
Sotos Syndrome
Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort.
Sotos Syndrome
The Structure of NSD1 Reveals an Autoregulatory Mechanism Underlying Histone H3K36 Methylation.
Squamous Cell Carcinoma of Head and Neck
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation.
Squamous Cell Carcinoma of Head and Neck
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Starvation
A metabolic throttle regulates the epigenetic state of rDNA.
Starvation
Epigenetic regulation of starvation-induced autophagy in Drosophila by histone methyltransferase G9a.
Starvation
Ischemic Preconditioning Confers Epigenetic Repression of Mtor and Induction of Autophagy Through G9a-Dependent H3K9 Dimethylation.
Starvation
lncRNA recruits RNAi and the exosome to dynamically regulate pho1 expression in response to phosphate levels in fission yeast.
Starvation
Regulation of Epigenetic Modifiers, Including KDM6B, by Interferon-? and Interleukin-4 in Human Macrophages.
Stomach Diseases
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Stomach Neoplasms
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Stomach Neoplasms
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Stomach Neoplasms
Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.
Stomach Neoplasms
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer.
Stomach Neoplasms
Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
Stomach Neoplasms
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Stomach Neoplasms
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Stomach Neoplasms
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Stomach Neoplasms
LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern.
Stomach Neoplasms
Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer.
Stomach Neoplasms
Retraction: Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
Stomach Neoplasms
SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ?Np63? protein.
Stomach Neoplasms
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Stomach Neoplasms
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Thyroid Cancer, Papillary
Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro.
Thyroid Carcinoma, Anaplastic
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Triple Negative Breast Neoplasms
Association Between Histone Methyltransferase hSETD1A and Prognosis in Patients With Triple-Negative Breast Cancer After Surgery: A Retrospective Study in the Chinese Female Population.
Triple Negative Breast Neoplasms
Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Triple Negative Breast Neoplasms
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
ulp1 peptidase deficiency
Senp2 Regulates Adipose Lipid Storage by De-SUMOylation of Setdb1.
Urinary Bladder Neoplasms
Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit.
Urinary Bladder Neoplasms
EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.
Urinary Bladder Neoplasms
Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Non-Invasive Diagnosis and Prognosis in Bladder Cancer: A Two Center Prospective Study.
Urinary Bladder Neoplasms
Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.
Urinary Bladder Neoplasms
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
Uterine Cervical Neoplasms
A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.
Uterine Cervical Neoplasms
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Uterine Cervical Neoplasms
Novel strategies for molecular targeting to cancer.
Uterine Cervical Neoplasms
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
Uterine Cervical Neoplasms
SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.
Uterine Cervical Neoplasms
SUV39H1-Mediated DNMT1 is Participated in the Epigenetic Regulation of Smad3 in Cervical Cancer.
Uterine Cervical Neoplasms
The polycomb group protein EZH2 is a novel therapeutic target for cervical cancer.
Vascular Diseases
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Vascular System Injuries
Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.
Vascular System Injuries
Suv39h1 downregulation inhibits neointimal hyperplasia after vascular injury.
Vesicular Stomatitis
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Virus Diseases
Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection.
Virus Diseases
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Virus Diseases
The epigenetic regulator G9a mediates tolerance to RNA virus infection in Drosophila.
Virus Diseases
The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.
Wiskott-Aldrich Syndrome
Gene regulation of Wiskott-Aldrich syndrome protein and the human homolog of the Drosophila Su(var)3-9: WASP and SUV39H1, two adjacent genes at Xp11.23.
Wolf-Hirschhorn Syndrome
H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.
Wolf-Hirschhorn Syndrome
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
Wolf-Hirschhorn Syndrome
Retinoic acid inhibits histone methyltransferase Whsc1 during palatogenesis.
Wolf-Hirschhorn Syndrome
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Wolf-Hirschhorn Syndrome
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
Wolf-Hirschhorn Syndrome
WHSC1 links transcription elongation to HIRA-mediated histone H3.3 deposition.
Wolf-Hirschhorn Syndrome
WHSC1/NSD2 regulates immune infiltration in prostate cancer.
Wolf-Hirschhorn Syndrome
Wolf-Hirschhorn syndrome candidate 1 facilitates alveolar macrophage pyroptosis in sepsis-induced acute lung injury through NEK7-mediated NLRP3 inflammasome activation.
[histone h3]-lysine9 n-trimethyltransferase deficiency
An HP1 isoform-specific feedback mechanism regulates Suv39h1 activity under stress conditions.
[histone h3]-lysine9 n-trimethyltransferase deficiency
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
[histone h3]-lysine9 n-trimethyltransferase deficiency
Euchromatin histone methyltransferase 1 regulates cortical neuronal network development.
[histone h3]-lysine9 n-trimethyltransferase deficiency
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
[histone h3]-lysine9 n-trimethyltransferase deficiency
Maternal Setdb1 Is Required for Meiotic Progression and Preimplantation Development in Mouse.
[histone h3]-lysine9 n-trimethyltransferase deficiency
Neuronal network dysfunction in a model for Kleefstra syndrome mediated by enhanced NMDAR signaling.
[histone h3]-lysine9 n-trimethyltransferase deficiency
Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells.
[histone h3]-lysine9 n-trimethyltransferase deficiency
SETDB1-Mediated Cell Fate Transition between 2C-Like and Pluripotent States.
[histone h3]-lysine9 n-trimethyltransferase deficiency
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
[histone h3]-lysine9 n-trimethyltransferase deficiency
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
[histone h3]-lysine9 n-trimethyltransferase deficiency
The Histone Methyltransferase SETDB1 Modulates Survival of Spermatogonial Stem/Progenitor Cells Through NADPH Oxidase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2.1.1.355 [histone H3]-lysine9 N-trimethyltransferase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
